Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Total Liabilities (2016 - 2025)

International Stem Cell (ISCO) has disclosed Total Liabilities for 16 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 3.31% to $4.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.8 million, a 3.31% decrease, with the full-year FY2024 number at $4.8 million, down 8.98% from a year prior.
  • Total Liabilities was $4.8 million for Q3 2025 at International Stem Cell, down from $5.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $6.4 million in Q1 2021 to a low of $4.8 million in Q3 2025.
  • A 5-year average of $5.3 million and a median of $5.3 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: increased 18.42% in 2021, then fell 11.06% in 2022.
  • International Stem Cell's Total Liabilities stood at $5.2 million in 2021, then rose by 2.31% to $5.4 million in 2022, then fell by 1.46% to $5.3 million in 2023, then decreased by 8.98% to $4.8 million in 2024, then decreased by 0.94% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Total Liabilities are $4.8 million (Q3 2025), $5.1 million (Q2 2025), and $5.4 million (Q1 2025).